title: First Oncolytic Viral Therapy for Melanoma.
abstract: The FDA has approved talimogene laherparepvec, or T-VEC, to treat surgically unresectable skin and lymph node lesions in patients with advanced melanoma. T-VEC is the first oncolytic viral therapy to gain regulatory endorsement, based on data from the OPTiM study.
authors.forename: Alissa
authors.initials: A
authors.lastname: Poh
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods; D050504:Oncolytic Viruses / Q000276:immunology / Q000502:physiology*; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab